Predicting Response to Selinexor Treatment in Relapsed Multiple Myeloma
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This study tests whether doctors can predict which patients with relapsed or hard-to-treat multiple myeloma will respond well to a drug called selinexor. Researchers will collect blood and bone marrow samples to identify markers that help personalize treatment decisions.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Confirmed diagnosis of multiple myeloma based on bone marrow testing
- Cancer has come back or stopped responding after 2–4 prior treatment lines
- Age 18 or older
- Any side effects from previous chemotherapy have recovered to mild levels or baseline
- Able to provide written consent and participate in follow-up visits and sample collection
- No other active cancers or serious heart, liver, or kidney disease
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving two medicines, called selinexor and melphalan, twice a week after a stem cell transplant can help prevent acute myeloid leukemia from coming back. It's for people with high-risk AML who are 55 or older and whose cancer is in remission before the transplant.
This trial tests a new drug called selinexor (KPT-330) combined with various standard treatments for patients whose multiple myeloma has come back or stopped responding to therapy. The goal is to see if adding selinexor helps control the cancer better than current options, and to find the safest dose for different drug pairings.
This trial tests a combination of four drugs (selinexor, carfilzomib, isatuximab, and dexamethasone) in patients whose multiple myeloma has come back or stopped responding to prior treatment. The goal is to see if this combination can shrink the cancer and help patients whose disease has high-risk features, like certain chromosome changes.
This study tests a new combination of drugs for people with multiple myeloma that has stopped responding to previous treatments. The goal is to see if adding selinexor to other anti-myeloma drugs can help control the disease.
This trial tests a three-drug combination (selinexor, ruxolitinib, and methylprednisolone) for people with multiple myeloma that has come back or stopped responding after at least three prior treatments. The goal is to see if this new combination can help control the cancer.
This study tests the drug selinexor in combination with a bispecific antibody for multiple myeloma that has already been treated with at least 4 prior therapies. The goal is to see if the combination is safe and effective for patients whose disease has returned or hasn’t responded to previous treatments.
Hear when a new Multiple Myeloma of Bone trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.